MANUFACTURING
SBV Technology and Eradicating the Risk of Contamination in Aseptic Manufacturing (Figure:1)
Containment is key during aseptic processing and this has led to the development of new transfer methods that are both enclosed and minimise the requirement for operator intervention. In this article, the author discusses modern containment methods and the advent of split butterly valve technology to improve production processes.. Christian Dunne, Global Product Manager ChargePoint Technology
Introduction
The global CMO Market is growing at a CAGR of 12–13 per cent between 2018 and 2022. The growth is attributed to increased outsourcing of generic drugs by Big Pharma companies. Additionally, medium and small pharma and biopharma companies, who do not possess adequate infrastructure, will also outsource, thereby driving the market.
58
P H A RM A F O C U S A S I A
ISSUE 39 - 2020
Presently, non-sterile drug manufacturing dominates the global CMO market. However, the sterile manufacturing market is expected to grow at a higher rate (15 per cent) than the non-sterile market (9 per cent) thru 2022. Aseptic Processing
Manufacturing environments contain many potential sources of contamina-
tion which present significant hazards during the manufacturing of biopharma products. It’s important for firms to ensure successful containment to prevent endotoxins, microorganisms or particles entering the manufacturing environment as this could put patient safety at risk. Equipment, materials, and people within the manufacturing environment can all offer potential sources of
